

**DEPARTMENT OF DEFENSE****Office of the Secretary****[Transmittal No. 07–21]****36(b)(1) Arms Sales Notification****AGENCY:** Department of Defense, Defense Security Cooperation Agency.**ACTION:** Notice.

**SUMMARY:** The Department of Defense is publishing the unclassified text of a section 36(b)(1) arms sales notification. This is published to fulfill the requirements of section 155 of Public Law 104–164, dated 21 July 1996.

**FOR FURTHER INFORMATION CONTACT:** Ms. J. Hurd, DSCA/DBO/CFM, (703) 604–6575.

The following is a copy of a letter to the Speaker of the House of Representatives, Transmittal 07–21 with attached transmittal and policy justification.

Dated: April 24, 2007.

**L.M. Bynum,**  
*ODS Federal Register Liaison Officer,*  
*Department of Defense.*

**BILLING CODE 5001–06–M**



## DEFENSE SECURITY COOPERATION AGENCY

WASHINGTON, DC 20301-2800

APR 20 2007

In reply refer to:  
I-07/003854

The Honorable Nancy Pelosi  
Speaker of the House of Representatives  
Washington, DC 20515-6501

Dear Madam Speaker:

Pursuant to the reporting requirements of Section 36(b)(1) of the Arms Export Control Act, as amended, we are forwarding herewith Transmittal No.

07-21, concerning the Department of the Air Force's proposed Letter(s) of Offer and Acceptance to Israel for defense articles and services estimated to cost \$65 million.

After this letter is delivered to your office, we plan to issue a press statement to notify the public of this proposed sale.

Sincerely,

A handwritten signature in cursive script, reading "Richard J. Millies", is positioned above the typed name and title.

Richard J. Millies  
Deputy Director

Enclosures:

1. Transmittal
2. Policy Justification

Same ltr to:

House

Committee on Foreign Affairs  
Committee on Armed Services  
Committee on Appropriations

Senate

Committee on Foreign Relations  
Committee on Armed Services  
Committee on Appropriations

**Transmittal No. 07-21**

**Notice of Proposed Issuance of Letter of Offer  
Pursuant to Section 36(b)(1)  
of the Arms Export Control Act, as amended (U)**

- (i) **Prospective Purchaser:** Israel
- (ii) **Total Estimated Value:**
- |                          |                     |
|--------------------------|---------------------|
| Major Defense Equipment* | \$60 million        |
| Other                    | <u>\$ 5 million</u> |
| TOTAL                    | \$65 million        |
- (iii) **Description and Quantity or Quantities of Articles or Services under Consideration for Purchase:** 3,500 MK-84 (Tritonal) general purpose bomb units, testing, support equipment, spares and repair parts, supply support, personnel training and training equipment, publications and technical data, U.S. Government and contractor technical assistance and other related elements of logistics support.
- (iv) **Military Department:** Air Force (AMV)
- (v) **Prior Related Cases, if any:**
- FMS case AMI - \$12 million - 25Jul06  
FMS case YET - \$22 million - 9Sep02  
FMS case YEQ - \$34 million - 9Feb00
- (vi) **Sales Commission, Fee, etc., Paid, Offered, or Agreed to be Paid:** none
- (vii) **Sensitivity of Technology Contained in the Defense Article or Defense Services Proposed to be Sold:** None
- (viii) **Date Report Delivered to Congress:** APR 20 2007

\* as defined in Section 47(6) of the Arms Export Control Act.

## **POLICY JUSTIFICATION**

### **Israel - MK-84 (Tritonal) General Purpose Bombs**

**The Government of Israel has requested a possible sale of 3,500 MK-84 (Tritonal) general purpose bomb units, testing, support equipment, spares and repair parts, supply support, personnel training and training equipment, publications and technical data, U.S. Government and contractor technical assistance and other related elements of logistics support. The estimated cost is \$65 million.**

**Israel's strategic position makes it vital to United States' interests throughout the Middle East. Our policy has been to promote Middle East peace, support Israeli commitment to peace with other regional Arab countries, enhance regional stability and promote Israeli readiness and self-sufficiency. It is vital to the U.S. national interest to assist Israel in developing and maintaining a strong and ready self-defense capability. This proposed sale is consistent with those objectives.**

**Israel has already integrated the MK-84 into its aircraft combat systems. It will have no difficulty absorbing these additional bombs into its armed forces.**

**The prime contractor will be General Dynamics, Garland, Texas. There are no known offset agreements in connection with this proposed sale.**

**Implementation of this sale will not require the assignment of any additional U. S. Government personnel in-country.**

**There will be no adverse impact on U.S. defense readiness as a result of this proposed sale.**

[FR Doc. 07-2098 Filed 4-27-07; 8:45 am]  
BILLING CODE 5001-06-C

#### **DEPARTMENT OF DEFENSE**

##### **Office of the Secretary**

##### **Meeting of the Uniform Formulary Beneficiary Advisory Panel**

**AGENCY:** Department of Defense, Assistant Secretary of Defense (Health Affairs).

**ACTION:** Notice of meeting.

**SUMMARY:** This notice announces a meeting of the Uniform Formulary Beneficiary Advisory Panel. The panel will review and comment on recommendations made to the Director, TRICARE Management Activity, by the Pharmacy and Therapeutics Committee regarding the Uniform Formulary. The meeting will be open to the public.

Seating is limited and will be provided only to the first 220 people signing in. All persons must sign in legibly. Notice of this meeting is required under the Federal Advisory Committee Act.

**DATES:** Thursday, June 21, 2007, from 8 a.m. to 4 p.m.

**ADDRESSES:** Naval Heritage Center Theater, 701 Pennsylvania Avenue, NW., Washington, DC 20004

**FOR FURTHER INFORMATION CONTACT:** Major Travis Watson, TRICARE Management Activity, Pharmaceutical Operations Directorate, Beneficiary Advisory Panel, Suite 810, 5111 Leesburg Pike, Falls Church, VA 22041, telephone 703-681-2890, fax 703-681-1940, or e-mail at [baprequests@tma.osd.mil](mailto:baprequests@tma.osd.mil).

**SUPPLEMENTARY INFORMATION:** The Uniform Formulary Beneficiary Advisory Panel will only review and comment on the development of the

Uniform Formulary as reflected in the recommendations of the DOD Pharmacy and Therapeutics (P&T) Committee coming out of that body's meeting in May 2007. The P&T Committee information and subject matter concerning drug classes reviewed for that meeting are available at <http://pec.ha.osd.mil>. Any private citizen is permitted to file a written statement with the advisory panel. Statement must be submitted electronically to [baprequests@tma.osd.mil](mailto:baprequests@tma.osd.mil) no later than June 14, 2007. Any private citizen is permitted to speak at the Beneficiary Advisory Panel meeting, time permitting. One hour will be reserved for public comments, and speaking times will be assigned only to the first twelve citizens to sign up at the meeting, on a first-come, first-served basis. The amount of time allocated to a speaker will not exceed five minutes.